Huntington aggregates may not predict neuronal death in Huntington's disease
- PMID: 10589536
Huntington aggregates may not predict neuronal death in Huntington's disease
Abstract
The mechanism by which polyglutamine expansion in Huntington's disease (HD) results in selective neuronal degeneration remains unclear. We previously reported that the immunohistochemical distribution of N-terminal huntingtin in HD does not correspond to the severity of neuropathology, such that significantly greater numbers of huntingtin aggregates are present within the cortex than in the striatum. We now show a dissociation between huntingtin aggregation and the selective pattern of striatal neuron loss observed in HD. Aggregate formation was predominantly observed in spared interneurons, with few or no aggregates found within vulnerable spiny striatal neurons. Multiple perikaryal aggregates were present in almost all cortical NADPH-diaphorase neurons and in approximately 50% of the spared NADPH-diaphorase striatal neurons from early grade HD cases. In severe grade HD patients, aggregates were more prominent as nuclear inclusions in NADPH-diaphorase neurons, with less perikaryal and neuropil aggregation. In contrast, nuclear or perikaryal huntingtin aggregates were present in less than 4% of the vulnerable calbindin striatal neurons in all HD cases. These findings support the hypothesis that polyglutamine aggregation may not be a predictor of cell loss. Rather than a harbinger of neuronal death, mutant huntingtin aggregation may be a cytoprotective mechanism against polyglutamine-induced neurotoxicity.
Similar articles
-
Huntingtin localization in brains of normal and Huntington's disease patients.Ann Neurol. 1997 Oct;42(4):604-12. doi: 10.1002/ana.410420411. Ann Neurol. 1997. PMID: 9382472
-
The selective vulnerability of nerve cells in Huntington's disease.Neuropathol Appl Neurobiol. 2001 Feb;27(1):1-21. doi: 10.1046/j.0305-1846.2001.00299.x. Neuropathol Appl Neurobiol. 2001. PMID: 11298997 Review.
-
Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease.J Neuropathol Exp Neurol. 1999 Feb;58(2):165-73. doi: 10.1097/00005072-199902000-00006. J Neuropathol Exp Neurol. 1999. PMID: 10029099
-
Huntington's disease intranuclear inclusions contain truncated, ubiquitinated huntingtin protein.Exp Neurol. 1999 Mar;156(1):92-9. doi: 10.1006/exnr.1998.7005. Exp Neurol. 1999. PMID: 10192780
-
Are there multiple pathways in the pathogenesis of Huntington's disease?Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):995-1003. doi: 10.1098/rstb.1999.0451. Philos Trans R Soc Lond B Biol Sci. 1999. PMID: 10434298 Free PMC article. Review.
Cited by
-
Disruption of Purkinje cell function prior to huntingtin accumulation and cell loss in an animal model of Huntington disease.Exp Neurol. 2012 Jul;236(1):171-8. doi: 10.1016/j.expneurol.2012.04.015. Epub 2012 May 2. Exp Neurol. 2012. PMID: 22579526 Free PMC article.
-
A Genome Scale Screen for Mutants with Delayed Exit from Mitosis: Ire1-Independent Induction of Autophagy Integrates ER Homeostasis into Mitotic Lifespan.PLoS Genet. 2015 Aug 6;11(8):e1005429. doi: 10.1371/journal.pgen.1005429. eCollection 2015 Aug. PLoS Genet. 2015. PMID: 26247883 Free PMC article.
-
Molecular Pathophysiological Mechanisms in Huntington's Disease.Biomedicines. 2022 Jun 17;10(6):1432. doi: 10.3390/biomedicines10061432. Biomedicines. 2022. PMID: 35740453 Free PMC article. Review.
-
Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x. CNS Neurosci Ther. 2012. PMID: 21501423 Free PMC article. Review.
-
Normal aging modulates the neurotoxicity of mutant huntingtin.PLoS One. 2009;4(2):e4637. doi: 10.1371/journal.pone.0004637. Epub 2009 Feb 27. PLoS One. 2009. PMID: 19247483 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical